NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group

Engages Apaton Finance to Provide Investor Relations Services in Europe

Vancouver, British Columbia–(Newsfile Corp. – March 23, 2022) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the 2022 Virtual Growth Conference presented by Maxim Group, being held virtually on March 28-30, 2022.

Paul Brennan, NervGen’s President and CEO, will provide an overview of the Company’s operations and the development plans for its lead compound, NVG-291. The presentation will be available via webcast on demand starting on Monday, March 28, 2022, at 9:00am ET using the following link:

https://m-vest.com/events/2022-virtual-growth-conference

NervGen is currently in Phase 1 clinical trials with NVG-291. Following completion of its Phase 1, NervGen intends to initiate Phase 1b/2 trials in Alzheimer’s disease, multiple sclerosis and spinal cord injury with the first trials planned to start in 2022.

NervGen is also pleased to announce the appointment of Apaton Finance GmbH (“Apaton”) as its public relations and investor relations consultant focused in the European Union, effective from March 18, 2022 for a one-year term. Apaton is a Hannover, Germany-based agency specializing in financial public relations and investor relations with a focus on small to mid-cap listed companies. Apaton will receive cash compensation, paid periodically, and is not anticipated to exceed US$60,000 over the term of the agreement. Apaton does not have any direct or indirect interest in NervGen, or its securities and no incentive stock options have been granted to Apaton. The appointment of Apaton as a public relations and investor relations consultant to NervGen is subject to regulatory acceptance of applicable filings with the TSX Venture Exchange.

About Apaton

Apaton Finance GmbH, is a specialist financial, public relations and investor relations agency, based in Hannover, Germany, providing services to international companies, with a focus on small to mid-cap listed companies. For more information, go to https://www.apaton.de/.

About NervGen

NervGen is restoring life’s potential by creating innovative treatments for nervous system damage due to injury or disease. The Company is initially developing treatments for Alzheimer’s disease, multiple sclerosis and spinal cord injury. For more information, go to www.nervgen.com.

For further information, please contact:

Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094

Nancy Thompson, Vorticom Public Relations
nancyt@vorticom.com
212.532.2208

Follow NervGen on Twitter, LinkedIn, and Facebook for the latest news on the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “trend”, “indication”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the expected compensation payable to Apaton; the timing of the clinical development of NVG-291; our clinical trial designs and timing to evaluate the therapeutic potential of NVG-291 in patients in Phase 1b/2 clinical trials in Alzheimer’s disease, multiple sclerosis and spinal cord injury upon successful completion of the Phase 1 trial; and the creation of innovative treatments of nervous system damage due to trauma or disease.

Forward-looking statements are based on estimates and assumptions made by the Company in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: the Company’s ability to manage the effects of the COVID-19 pandemic; the accuracy of the Company’s financial projections; the Company obtaining positive results in its clinical and other trials; the Company obtaining necessary regulatory approvals; and general business, market and economic conditions.

Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, the impact of the COVID-19 pandemic, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the “Risk Factors” section of the Company’s Annual Information Form, Prospectus Supplement, financial statements and Management Discussion and Analysis which can be found on SEDAR.com. All clinical development plans are subject to additional funding.

Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/117754